Navigation Links
Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Apr 12, 2007 - Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that four posters containing preclinical data will be presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) to be held from April 14 - 18, 2007 in Los Angeles, CA.

Details of the presentations are as follows:

-- Abstract #1494: EZN-2208, a novel polyethyleneglycol-SN38 conjugate, has potent antitumor activity in a panel of human tumor xenografts (Poster displayed on Sunday, April 15, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 30, Poster Board 8.)

-- Abstract #1496: EZN-2208, a novel poly ethylene glycol-SN38 conjugate, improves pharmacological properties of SN38 in mice and rats. (Poster displayed on Sunday, April 15, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 30, Poster Board 10.)

-- Abstract #4731: Customized positive PEG linkers for the delivery of antisense molecules (Poster displayed on Tuesday, April 17, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 25, Poster Board 14.)

-- Abstract #4726: In vitro and in vivo evaluation of PEGylated anti-Bcl2 siRNA conjugates in a Bcl-2 over-expressing lung cancer model (Poster displayed on Tuesday, April 17, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 25, Poster Board 9.)

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two o
'"/>




Page: 1 2

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:6/18/2013)... 18, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... announced today that VPII Escrow Corp., a newly formed ... its offer of approximately $3.2 billion aggregate principal amount ... be due in 2021 and in 2023, with final ... to use the net proceeds from the offering, together ...
(Date:6/18/2013)... , June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... focused on the development and commercialization of novel bile ... the pricing of an underwritten public offering of 1,730,000 ... price of $33.01 per share.  In addition, Intercept has ... to an additional 259,500 shares of common stock. ...
(Date:6/18/2013)... Valeant Pharmaceuticals International, Inc. (NYSE: ... announced public offering of common shares (the "Offering"). Pursuant ... shares at a price of $85.00 per share, for ... will file a final prospectus supplement to its effective ... a similar filing with the securities regulatory authorities in ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... Sept. 16 Boston Scientific Corporation (NYSE: ... Drug Administration (FDA) has approved an expanded indication for ... CRT-D.  The exclusive expanded indication is effective immediately and ... the FDA for patients in all New York Heart ...
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory ... do not adequately demonstrate that the potential benefits of ... a population of overweight and obese individuals to allow ...
Cached Medicine Technology:Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds 2Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds 3Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds 4Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 2Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 3Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 4
(Date:6/18/2013)... New York (PRWEB) June 18, 2013 ... dedicated to protecting the rights of victims injured by ... University’s independent review of Medtronic’s Infuse bone graft products ... Internal Medicine, a medical journal, the two studies serve ... difference in effectiveness” when comparing Infuse and the traditional ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Biomet ... continue to move forward in a multidistrict litigation in ... LLP reports. According to court records, the litigation’s ... at which time the Court also convened a motions ... issues pertinent to the Biomet hip replacement litigation. ...
(Date:6/18/2013)... shown that cancer cells have a much different ... scientists at The University of Texas at Dallas have ... strategy to combat lung cancer. , In an article ... ONE , UT Dallas researchers compared the metabolic characteristics ... taken from the same patient. , They found ...
(Date:6/18/2013)... More than 1.1 million people in the U.S. ages 13 ... for Disease Control and Prevention (CDC). Of those, nearly 20 ... HIV Testing Day on June 27, Allsup, a nationwide provider ... CDC and other organizations are raising awareness of the importance ... new HIV infections each year. Along with developing AIDS, those ...
(Date:6/18/2013)... Two months ago, Suyima Torres, 28, died from respiratory ... of a silicone treatment for gluteus augmentation at Cuerpos Health ... by a mystery Venezuelan doctor in a center that was ... Vazquez of Bayshore Cosmetic Surgery , women suffering from ... not board certified is more common than people think. ...
Breaking Medicine News(10 mins):Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3
... Defend Intellectual Property RightsINDIANAPOLIS, March 9 Eli Lilly ... the following statement after being granted a temporary restraining ... of Evista(R) (raloxifene HCl tablets) by Teva Pharmaceuticals. Teva ... version prior to the resolution of outstanding patent litigation ...
... Neogen Corporation (Nasdaq: NEOG ) announced ... common stock repurchase program. In December, Neogen,s Board of ... have been, and additional shares are expected to be, ... depending on market conditions and other factors. Accordingly, there ...
... renders melanomas sensitive to retinoic acid and stops tumor ... cancer therapies such as radiotherapy, chemotherapy, and retinoic acid ... the prognosis for patients is often poor. However, Vincent ... the National Institutes of Health in Bethesda, Maryland, have ...
... Akerman Senterfitt today announced that Julie Gallagher has joined ... Healthcare Practice Group. Ms. Gallagher,s work focuses on ... companies, individual health care providers and health care facilities. ... she spent seven years as a shareholder."We are very ...
... to Announce Fiscal Third Quarter Results on ... Allscripts-Misys Healthcare Solutions, Inc. ("Allscripts") announced today ... to sell its Medication Services business to ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO )The transaction, which is anticipated ...
... Inc. (Nasdaq: KERX ) today announced that ... Listings Qualification Panel ("Panel") the determination of The Nasdaq ... The Nasdaq Capital Market due to noncompliance with Nasdaq ... a minimum of $2,500,000 in stockholders, equity, or $35,000,000 ...
Cached Medicine News:Health News:Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene 2Health News:Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene 3Health News:Neogen Reactivates Share Repurchase Program 2Health News:JCI online early table of contents: March 9, 2009 2Health News:JCI online early table of contents: March 9, 2009 3Health News:JCI online early table of contents: March 9, 2009 4Health News:JCI online early table of contents: March 9, 2009 5Health News:Julie Gallagher Joins Akerman Senterfitt's Healthcare Practice 2Health News:Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement 2Health News:Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement 3Health News:Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement 4Health News:Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq 2Health News:Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: